Review
Biochemistry & Molecular Biology
Hua-Min Zhang, Shuo Yuan, Huan Meng, Xiao-Ting Hou, Jiao Li, Jia-Chen Xue, You Li, Qi Wang, Ji-Xing Nan, Xue-Jun Jin, Qing-Gao Zhang
Summary: Inflammatory bowel disease (IBD) is a chronic, relapsing disease that greatly affects patients' quality of life. Stem cell therapy has shown potential to improve the clinical disease activity of patients with refractory IBD when conventional treatments are not effective, but its safety and long-term efficacy need further evaluation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Pharmacology & Pharmacy
Badr Al-Bawardy, Raina Shivashankar, Deborah D. Proctor
Summary: This review discusses novel therapeutic targets for inflammatory bowel diseases, including selective JAK inhibitors, anti-interleukin drugs, leukocyte migration inhibitors, and other small molecules currently in development.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Elisabetta Bretto, Davide Giuseppe Ribaldone, Gian Paolo Caviglia, Giorgio Maria Saracco, Elisabetta Bugianesi, Simone Frara
Summary: Inflammatory bowel disease (IBD) refers to a group of chronic, relapsing inflammatory disorders of the gastrointestinal tract, including Crohn's disease and ulcerative colitis. The global incidence and prevalence of IBD have been increasing, and although the specific causes are still unknown, immunological, genetic, and environmental factors are believed to play a role. The development of biologic therapies in the past few decades has greatly improved the treatment of IBD, but there is still no definitive cure and some patients may not respond well to available therapies. However, emerging therapies targeting new pathogenic mechanisms show promising efficacy and safety in early clinical trials, and their potential significance in shaping future treatment options is being emphasized.
Review
Medicine, General & Internal
Daniel C. Baumgart, Catherine Le Berre
Summary: This review discusses newer biologic and small-molecule therapies for inflammatory bowel disease, emphasizing the importance of achieving clinical and endoscopic remission as well as more precise molecular targeting of inflammatory cascades.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Joseph Meredith, Cher-Antonia Khedim, Paul Henderson, David C. Wilson, Richard K. Russell
Summary: PIMS-TS is a newly described pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. The patient in this case study showed improvement after treatment with high-dose methylprednisolone.
JOURNAL OF CROHNS & COLITIS
(2021)
Review
Gastroenterology & Hepatology
Laurie B. Grossberg, Konstantinos Papamichael, Adam S. Cheifetz
Summary: This review examines the mechanisms of action and clinical trial data of emerging drug therapies for inflammatory bowel disease (IBD). The results show that several new therapies have demonstrated positive efficacy and safety data in early clinical trials for both ulcerative colitis (UC) and Crohn's disease (CD). As more treatments for IBD are approved, further research is needed to identify predictors of response and conduct head-to-head trials to guide therapeutic options for patients.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Gastroenterology & Hepatology
Stefan Schreiber, Shomron Ben-Horin, Jaroslaw Leszczyszyn, Robert Dudkowiak, Adi Lahat, Beata Gawdis-Wojnarska, Aldis Pukitis, Marek Horynski, Katalin Farkas, Jaroslaw Kierkus, Maciej Kowalski, Sang Joon Lee, Sung Hyun Kim, Jee Hye Suh, Mi Rim Kim, Seul Gi Lee, Byong Duk Ye, Walter Reinisch
Summary: This study demonstrated the pharmacokinetic noninferiority of CT-P13 SC to CT-P13 IV, with comparable clinical remission rates between the two formulations.
Article
Gastroenterology & Hepatology
Hiroshi Nakase, Yuki Hayashi, Daisuke Hirayama, Takayuki Matsumoto, Minoru Matsuura, Hideki Iijima, Katsuyoshi Matsuoka, Naoki Ohmiya, Shunji Ishihara, Fumihito Hirai, Daiki Abukawa, Tadakazu Hisamatsu
Summary: The incidence of COVID-19 among Japanese IBD patients was low, with most patients being in clinical remission and only a small number of severe cases. Age, BMI, and steroid use were identified as independent risk factors for COVID-19 severity in Japanese IBD patients.
JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Pharmacology & Pharmacy
Lauren J. Mohan, Jacqueline S. Daly, Barbara M. Ryan, Zebunnissa Ramtoola
Summary: This study investigated the potential of nanomedicines in the treatment of inflammatory bowel diseases (IBD). The results showed that the size of nanoparticles can modulate the targeting effect on the intestinal epithelial barrier, delivering the drug directly to the inflamed tissue and reducing inflammation and cytotoxicity.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
(2023)
Review
Nutrition & Dietetics
Elizabeth A. A. Reznikov, David L. L. Suskind
Summary: Inflammatory Bowel Disease (IBD) is a group of chronic immune-mediated intestinal diseases associated with the interaction between the immune system and the intestinal microbiome. Nutritional therapy is supported in IBD but not commonly used in clinical practice. This literature review aims to enhance the understanding of diet's impact on IBD, focusing on Crohn's Disease (CD) and Ulcerative Colitis (UC). The contribution of diet to the development and treatment of IBD is significant, with nutritional interventions improving symptoms and inflammation burden.
Article
Gastroenterology & Hepatology
Ryusuke Nambu, Takahiro Kudo, Nao Tachibana, Hirotaka Shimizu, Tatsuki Mizuochi, Sawako Kato, Mikihiro Inoue, Hideki Kumagai, Takashi Ishige, Reiko Kunisaki, Atsuko Noguchi, Toshifumi Yodoshi, Shin-Ichiro Hagiwara, Shigeo Nishimata, Fumihiko Kakuta, Takeshi Saito, Itaru Iwama, Yuri Hirano, Toshiaki Shimizu, Katsuhiro Arai
Summary: In pediatric UC patients, approximately 50% underwent colectomy during a 2-year interval following IFX failure. Prognosis after IFX failure appeared to improve with availability of new biologic agents and small-molecule drugs in mid-2018.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Rebecca J. Gordon, Reeder Wells, Camille Johansen, Shanshan Liu, Suzanne E. Dahlberg, Scott B. Snapper, Paul A. Rufo
Summary: This study assessed the efficacy and safety of high-dose, interval cholecalciferol administration in IBD patients receiving infliximab. The results showed that cholecalciferol supplementation was well-tolerated, but high doses were required for patients with IBD to achieve vitamin D sufficiency.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
(2022)
Article
Microbiology
Jonathan Wei Jie Lee, Damian Plichta, Larson Hogstrom, Nynke Z. Borren, Helena Lau, Sara M. Gregory, William Tan, Hamed Khalili, Clary Clish, Hera Vlamakis, Ramnik J. Xavier, Ashwin N. Ananthakrishnan
Summary: The intestinal microbiome plays a key role in determining responses to biologic therapy in inflammatory bowel disease. Microbial profiles can help predict clinical therapeutic success and guide the selection of optimal treatments for patients.
CELL HOST & MICROBE
(2021)
Review
Biochemistry & Molecular Biology
Chaoyue Chen, Wei Yan, Meihui Tao, Yu Fu
Summary: Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a complex inflammatory immune response. Nicotinamide adenine dinucleotide (NAD(+)) has important roles in cellular processes. The relationship between inflammatory diseases and NAD(+) metabolism is being recognized. Therapeutics targeting the NAD(+) pathway show promise in managing IBD. This review examines the molecular biology and pathophysiology of NAD(+) in IBD and provides evidence for the clinical use of NAD(+) in IBD.
Review
Gastroenterology & Hepatology
Shubha Bhat, Benjamin Click, Miguel Regueiro
Summary: The recent approval of new medications and updated safety information has changed the treatment landscape of inflammatory bowel disease (IBD). This review examines the safety data of monoclonal antibodies and small molecules for IBD, focusing on recently FDA-approved therapies, and proposes risk stratification and assessment considerations for IBD treatment.
INFLAMMATORY BOWEL DISEASES
(2023)
